{"analyses":[{"ciLowerLimit":"0.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1453","paramType":"Hazard Ratio (HR)","paramValue":"1.11","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"12.0","value":"11.0"},{"groupId":"OG001","lowerLimit":"9.0","upperLimit":"11.0","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"761"},{"groupId":"OG001","value":"764"}],"units":"Participants"}],"description":"Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day.\n\nNIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"MEDIAN","populationDescription":"All participants randomly assigned to study intervention.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Time to Recovery","type":"SECONDARY","unitOfMeasure":"days"}